EGFR and non-small cell lung carcinoma: Another study targeting EGFR ex20ins mutant NSCLC patients with ≥ 2 lines showed that the overall ORR and DCR of 15 patients receiving furmonertinib treatment were 53.5%, 100%, and the 3-month PFS rate was 100% (22).